{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:05:44Z","timestamp":1784948744450,"version":"3.55.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"34","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001030","name":"Australian National Heart Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Monash University Faculty of Medicine"},{"name":"Nursing and Health Sciences"},{"name":"National Heart Foundation Future Leader Fellowship","award":["102604"],"award-info":[{"award-number":["102604"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The aim of this study was to assess the impact and cost-effectiveness of offering population genomic screening to all young adults in Australia to detect heterozygous familial hypercholesterolaemia (FH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We designed a decision analytic Markov model to compare the current standard of care for heterozygous FH diagnosis in Australia (opportunistic cholesterol screening and genetic cascade testing) with the alternate strategy of population genomic screening of adults aged 18\u201340 years to detect pathogenic variants in the LDLR\/APOB\/PCSK9 genes. We used a validated cost-adaptation method to adapt findings to eight high-income countries. The model captured coronary heart disease (CHD) morbidity\/mortality over a lifetime horizon, from healthcare and societal perspectives. Risk of CHD, treatment effects, prevalence, and healthcare costs were estimated from published studies. Outcomes included quality-adjusted life years (QALYs), costs and incremental cost-effectiveness ratio (ICER), discounted 5% annually. Sensitivity analyses were undertaken to explore the impact of key input parameters on the robustness of the model. Over the lifetime of the population (4 167 768 men; 4 129 961 women), the model estimated a gain of 33 488years of life lived and 51 790 QALYs due to CHD prevention. Population genomic screening for FH would be cost-effective from a healthcare perspective if the per-test cost was \u2264AU$250, yielding an ICER of &amp;lt;AU$28 000 per QALY gained. From a societal perspective, population genomic screening would be cost-saving. ICERs from societal perspective remained cost-saving after adaptation to other countries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Based on our model, offering population genomic screening to all young adults for FH could be cost-effective, at testing costs that are feasible.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab770","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T11:08:16Z","timestamp":1634900896000},"page":"3243-3254","source":"Crossref","is-referenced-by-count":35,"title":["Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2582-0374","authenticated-orcid":false,"given":"Clara","family":"Marquina","sequence":"first","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , 553 St Kilda Rd, Melbourne, VIC 3004 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0902-6798","authenticated-orcid":false,"given":"Paul","family":"Lacaze","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , 553 St Kilda Rd, Melbourne, VIC 3004 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3906-6632","authenticated-orcid":false,"given":"Jane","family":"Tiller","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , 553 St Kilda Rd, Melbourne, VIC 3004 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeen","family":"Riaz","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , 553 St Kilda Rd, Melbourne, VIC 3004 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-7786","authenticated-orcid":false,"given":"Amy C","family":"Sturm","sequence":"additional","affiliation":[{"name":"Genomic Medicine Institute , 100 North Academy Avenue, Geisinger, PA 17822 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R","family":"Nelson","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , 553 St Kilda Rd, Melbourne, VIC 3004 , Australia"},{"name":"Menzies Institute for Medical Research , 17 Liverpool St, Hobart, TAS 7000 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A","family":"Ference","sequence":"additional","affiliation":[{"name":"University of Cambridge, Centre for Naturally Randomised Trials , The Old Schools, Trinity Ln, Cambridge CB2 1TN , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9700-6948","authenticated-orcid":false,"given":"Jing","family":"Pang","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia , 35 Stirling Hwy, Perth, WA 6009 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F","family":"Watts","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia , 35 Stirling Hwy, Perth, WA 6009 , Australia"},{"name":"Lipid Disorders Clinic, Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital , Victoria Square, Perth, WA 6000 , Australia"},{"name":"Lipid Disorders Clinic, Cardiometabolic Service, Department of Internal Medicine, Royal Perth Hospital , Victoria Square, Perth, WA 6000 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Nicholls","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , 553 St Kilda Rd, Melbourne, VIC 3004 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Zoungas","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , 553 St Kilda Rd, Melbourne, VIC 3004 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-623X","authenticated-orcid":false,"given":"Danny","family":"Liew","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , 553 St Kilda Rd, Melbourne, VIC 3004 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1049-5129","authenticated-orcid":false,"given":"John","family":"McNeil","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , 553 St Kilda Rd, Melbourne, VIC 3004 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-3522","authenticated-orcid":false,"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , 553 St Kilda Rd, Melbourne, VIC 3004 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"2022102610292175000_ehab770-B1","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022102610292175000_ehab770-B2","doi-asserted-by":"crossref","first-page":"aaf7000","DOI":"10.1126\/science.aaf7000","article-title":"Genetic identification of familial hypercholesterolemia within a single U.S. health care system","volume":"354","author":"Abul-Husn","year":"2016","journal-title":"Science"},{"key":"2022102610292175000_ehab770-B3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41569-019-0325-8","article-title":"Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care","volume":"17","author":"Watts","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2022102610292175000_ehab770-B4","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"key":"2022102610292175000_ehab770-B5","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of lipids on cardiovascular health: JACC Health Promotion Series","volume":"72","author":"Ference","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102610292175000_ehab770-B6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/CIRCULATIONAHA.116.022335","article-title":"Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype","volume":"134","author":"Perak","year":"2016","journal-title":"Circulation"},{"key":"2022102610292175000_ehab770-B7","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.hlc.2020.07.012","article-title":"Gaps in the care of familial hypercholesterolaemia in Australia: first Report from the National Registry","volume":"30","author":"Pang","year":"2021","journal-title":"Heart Lung Circ"},{"key":"2022102610292175000_ehab770-B8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.hlc.2020.09.943","article-title":"Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia","volume":"30","author":"Watts","year":"2021","journal-title":"Heart Lung Circ"},{"key":"2022102610292175000_ehab770-B9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2019.11.028","article-title":"Reaching detection targets in familial hypercholesterolaemia: comparison of identification strategies","volume":"293","author":"Wald","year":"2020","journal-title":"Atherosclerosis"},{"key":"2022102610292175000_ehab770-B10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5694\/mja16.00070","article-title":"Progress in the care of familial hypercholesterolaemia: 2016","volume":"205","author":"Bell","year":"2016","journal-title":"Med J Aust"},{"key":"2022102610292175000_ehab770-B11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ajmg.a.34368","article-title":"The evaluation of cascade testing for familial hypercholesterolemia","volume":"158A","author":"Morris","year":"2012","journal-title":"Am J Med Genet A"},{"key":"2022102610292175000_ehab770-B12","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacl.2014.05.008","article-title":"Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia","volume":"8","author":"Ademi","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2022102610292175000_ehab770-B13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacl.2019.01.009","article-title":"Comparative aspects of the care of familial hypercholesterolemia in the \u201cTen Countries Study\u201d","volume":"13","author":"Pang","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2022102610292175000_ehab770-B14","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.atherosclerosissup.2018.07.026","article-title":"Cost-effectiveness of universal screening for familial hypercholesterolaemia (FH) at age 1-2 years","volume":"34","author":"McKay","year":"2018","journal-title":"Atheroscler Suppl"},{"key":"2022102610292175000_ehab770-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.05.007","article-title":"Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment?","volume":"304","author":"Ademi","year":"2020","journal-title":"Atherosclerosis"},{"key":"2022102610292175000_ehab770-B16","first-page":"w14626","article-title":"Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight","volume":"148","author":"Ademi","year":"2018","journal-title":"Swiss Med Wkly"},{"key":"2022102610292175000_ehab770-B17","author":"Australian Bureau of Statistics","year":"2019"},{"key":"2022102610292175000_ehab770-B18","doi-asserted-by":"crossref","first-page":"e016461","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen","year":"2017","journal-title":"BMJ Open"},{"key":"2022102610292175000_ehab770-B19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/hrt.2010.210138","article-title":"Discordant age and sex-specific trends in the incidence of a first coronary heart disease event in Western Australia from 1996 to 2007","volume":"97","author":"Briffa","year":"2011","journal-title":"Heart"},{"key":"2022102610292175000_ehab770-B20","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwab001","article-title":"Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029","author":"Marquina","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2022102610292175000_ehab770-B21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jchf.2013.12.003","article-title":"Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (Valsartan In Acute Myocardial Infarction)","volume":"2","author":"Lewis","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2022102610292175000_ehab770-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2019.01.037","article-title":"The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: the Australian healthcare perspective","volume":"285","author":"Zomer","year":"2019","journal-title":"Int J Cardiol"},{"key":"2022102610292175000_ehab770-B23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"key":"2022102610292175000_ehab770-B24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12955-016-0537-0","article-title":"Health-related quality of life measured using the EQ-5D\u20135L: south Australian population norms","volume":"14","author":"McCaffrey","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"2022102610292175000_ehab770-B25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jnci\/dju379","article-title":"Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial","volume":"107","author":"Manchanda","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2022102610292175000_ehab770-B26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40273-017-0585-2","article-title":"Estimating the reference incremental cost-effectiveness ratio for the Australian health system","volume":"36","author":"Edney","year":"2018","journal-title":"PharmacoEconomics"},{"key":"2022102610292175000_ehab770-B27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.18773\/austprescr.2017.014","article-title":"Economic evaluation of medicines","volume":"40","author":"Taylor","year":"2017","journal-title":"Aust Prescr"},{"key":"2022102610292175000_ehab770-B28","author":"Department of Health. The Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines","year":"2021"},{"key":"2022102610292175000_ehab770-B29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","article-title":"Discounting in economic evaluations","volume":"36","author":"Attema","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2022102610292175000_ehab770-B30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/heartjnl-2015-307668","article-title":"Estimated 10-year cardiovascular mortality seriously underestimates overall cardiovascular risk","volume":"102","author":"J\u00f8rstad","year":"2016","journal-title":"Heart"},{"key":"2022102610292175000_ehab770-B31","author":"Australian Institute of Health and Welfare"},{"key":"2022102610292175000_ehab770-B32","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA"},{"key":"2022102610292175000_ehab770-B33","doi-asserted-by":"crossref","first-page":"e001236","DOI":"10.1161\/JAHA.114.001236","article-title":"Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992\u20132010","volume":"3","author":"Mundal","year":"2014","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"2022102610292175000_ehab770-B34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2015.03.027","article-title":"Prevalence and treatment of familial hypercholesterolaemia in Australian communities","volume":"185","author":"Watts","year":"2015","journal-title":"Int J Cardiol"},{"key":"2022102610292175000_ehab770-B35","author":"Australian Bureau of Statistics","year":"2015"},{"key":"2022102610292175000_ehab770-B36","author":"Australian Institute of Health and Welfare","year":"2019"},{"key":"2022102610292175000_ehab770-B37","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319896648","article-title":"The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction","author":"Ademi","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2022102610292175000_ehab770-B38","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/1471-2458-12-398","article-title":"Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study","volume":"12","author":"Cobiac","year":"2012","journal-title":"BMC Public Health"},{"key":"2022102610292175000_ehab770-B39","author":"Australia Governments, Department of Health"},{"key":"2022102610292175000_ehab770-B40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ Res"},{"key":"2022102610292175000_ehab770-B41","doi-asserted-by":"publisher","author":"Australian Institute of Health and Welfare","year":"2019","DOI":"10.25816\/5ec5ba12ed174"},{"key":"2022102610292175000_ehab770-B42","doi-asserted-by":"crossref","first-page":"i89","DOI":"10.1136\/ard.2009.117150","article-title":"The value of productivity: human-capital versus friction-cost method","volume":"69","author":"van den Hout","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2022102610292175000_ehab770-B43","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"2022102610292175000_ehab770-B44","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/jcm8071080","article-title":"Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: analysis of 5 years follow-up of real-world data from more than 1.5 million patients","volume":"8","author":"Masana","year":"2019","journal-title":"J Clin Med"},{"key":"2022102610292175000_ehab770-B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2021.100880","article-title":"Trends in the utilisation of lipid-lowering medications in Australia: an analysis of national pharmacy claims data","author":"Talic","year":"2021","journal-title":"Curr Probl Cardiol"},{"key":"2022102610292175000_ehab770-B46","doi-asserted-by":"crossref","first-page":"e1\u20135","DOI":"10.1016\/j.jval.2013.02.010","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"2022102610292175000_ehab770-B47"},{"key":"2022102610292175000_ehab770-B48","author":"Organization for Economic Co-operation and Development"},{"key":"2022102610292175000_ehab770-B49","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1602777","article-title":"Child\u2013parent familial hypercholesterolemia screening in primary care","volume":"375","author":"Wald","year":"2016","journal-title":"N Engl J Med"},{"key":"2022102610292175000_ehab770-B50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/s41436-020-01082-w","article-title":"DNA-based screening and population health: a points to consider statement for programs and sponsoring organizations from the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Murray","year":"2021","journal-title":"Genet Med"},{"key":"2022102610292175000_ehab770-B51","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000502917","article-title":"Healthcare system-funded preventive genomic screening: challenges for Australia and other single-payer systems","volume":"22","author":"Lacaze","year":"2019","journal-title":"Public Health Genomics"},{"key":"2022102610292175000_ehab770-B52","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/s41436-020-0876-4","article-title":"Clinical outcomes of a genomic screening program for actionable genetic conditions","volume":"22","author":"Buchanan","year":"2020","journal-title":"Genet Med"},{"key":"2022102610292175000_ehab770-B53","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41436-019-0457-6","article-title":"Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis","volume":"21","author":"Zhang","year":"2019","journal-title":"Genet Med"},{"key":"2022102610292175000_ehab770-B54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosis.2014.12.036","article-title":"Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience","volume":"239","author":"Bell","year":"2015","journal-title":"Atherosclerosis"},{"key":"2022102610292175000_ehab770-B55","doi-asserted-by":"crossref","first-page":"e203959","DOI":"10.1001\/jamanetworkopen.2020.3959","article-title":"Association of rare pathogenic DNA variants for familial hypercholesterolemia, hereditary breast and ovarian cancer syndrome, and lynch syndrome with disease risk in adults according to family history","volume":"3","author":"Patel","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2022102610292175000_ehab770-B56","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5694\/mja2.50922","article-title":"Monitoring the genetic testing and life insurance moratorium in Australia: a national research project","volume":"214","author":"Tiller","year":"2021","journal-title":"Med J Aust"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/34\/3243\/46642591\/ehab770.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/34\/3243\/46642591\/ehab770.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T10:46:20Z","timestamp":1666781180000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/34\/3243\/6425622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":56,"journal-issue":{"issue":"34","published-online":{"date-parts":[[2021,11,11]]},"published-print":{"date-parts":[[2022,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab770","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,7]]},"published":{"date-parts":[[2021,11,11]]}}}